Skip To Main Content
L. Barrera on Muck Rack

L. Barrera

As seen in: Annals of Oncology, El Periódico Extremadura
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with L.

Contact L., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Predictors of psychosocial adaptation in children with CHD

|
By Kiona Y. Allen, L. Barrera, M. Heffernan, Jessica L. Metelski
| dx.doi.org
Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-05T13:49:30.211Z Has data issue: false hasContentIssue false Published online by Cambridge University Press: 18 April 2024 Jessica L. Metelski [Opens in a new window] , Kiona Y. Allen [Opens in a new window] , L. Barrera [Opens in a new window] , M. Heffernan [Opens in a new window] , Clayton D. Hinkle [Opens in a new window] , Carolyn C.
Open in Who Shared Issue with article?

Pau Donés: "Yo tengo mis días de sol y mis días de sombra"

|
By L. Barrera
| El Periódico Extremadura Verified
0 L. BARRERAL. BARRERA Donés 07/09/2007 Este músico aragonés de 1966, líder de Jarabe de palo, llega a localidad extremeña de Aceuchal dentro de la gira de promoción de su último disco ´Adelantando´ Vivir deprisa. Esa es la sensación que desprendía Pau Donés, líder de Jarabe de Palo, tras una década de viajes y éxitos fulminantes. Desde La flaca a Depende o Bonito . Para sacar Adelantando , su último disco, que hoy presenta en Extremadura, hubieron de pasar, sin embargo, tres años.
Open in Who Shared Issue with article?

Clinical evaluation of the utility of a liquid biopsy (circulating tumoral cells and ctDNA) to determine the mutational profile (EGFR, KRAS, ALK, ROS1 and BRAF) in advanced NSCLC patients

|
By L. Barrera, E. Montes-Servin, J. R. Borbolla
| Annals of Oncology Verified
Background: Circulating tumor DNA (ctDNA) has emerged as a specific and sensitive blood-based biomarker for detection of several mutations in non–small-cell lung cancer (NSCLC). Other clinical applications include serial monitoring of biomarker status or the development of resistance mutations.
Open in Who Shared Issue with article?
See all 3 articles